Speaker(s): 

Caroline Baran, MD, DABOM, Staff Member, Geisinger - has nothing to disclosure 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Identify medications that either reduce the major modifiable risk factor for OSA
• Explain separate approved therapy from off-label or investigational options and emphasize what the evidence actually measured

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Manoj Suryanarayanan, MD; Sreelatha Naik, MD; Caroline Baran, MD; Jamie Karlotski, CRNP and Kimberly Persaud, DO have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session:

None